Oncotelic Presents PDAOAI Platform and HCC Four-Gene Signature
Oncotelic Therapeutics presented its PDAOAI platform and an exploratory four-gene mTOR-related signature linked to HCC survival at Drug Discovery 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.